Literature DB >> 23801129

The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.

Atsushi Hayashi1, Takumi Fumon, Yukari Miki, Hiaki Sato, Tadashi Yoshino, Kiyoshi Takahashi.   

Abstract

Thymic carcinoma (TC) is often very difficult to distinguish from type B3 thymoma and lung squamous cell carcinoma (L-SCC) involving the anterior mediastinum. The present study evaluated the usefulness of immunohistochemical markers including c-Kit, CD5, glucose transporter-1 (GLUT-1), claudin-1 (CLDN-1), thymoproteasome β5t, p53 and Ki-67 (MIB-1) and thymic cortical environmental marker cells, cortical thymocytes (c-Thy) and thymic cortical dendritic macrophages (TCDMs) in distinguishing thymic carcinoma (TC) from type B3 thymoma or lung squamous cell carcinoma (L-SCC) using 17 cases of type B3 thymoma, 18 cases of TC and 12 cases of L-SCC. The results indicated that c-Kit and CD5 are very useful markers for TC, while GLUT-1, CLDN-1, p53 and Ki-67 are not. Thymic cortical microenvironmental marker cells, especially TCDMs, and thymic cortical epithelial cell-marker β5t are also useful for distinguishing TC from type B3 thymoma. Although none of these markers are adequate for making a distinction when used alone, the plural use of c-Kit, CD5, β5t thymic cortical environmental marker cells, c-Thys and TCDMs may therefore lead to a correct distinction between TC and type B3 thymoma or L-SCC. [J Clin Exp Hematop 53(1) : 9-19, 2013].

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801129     DOI: 10.3960/jslrt.53.9

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  9 in total

Review 1.  Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors.

Authors:  Alexandra Papoudou-Bai; Alexandra Barbouti; Vassiliki Galani; Kalliopi Stefanaki; Dimitra Rontogianni; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2015-03-21       Impact factor: 3.984

2.  Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.

Authors:  Xue-Ying Su; Wei-Ya Wang; Jin-Nan Li; Dian-Ying Liao; Wei-Lu Wu; Gan-Di Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Atypical thymomas with squamoid and spindle cell features: clinicopathologic, immunohistochemical and molecular genetic study of 120 cases with long-term follow-up.

Authors:  David I Suster; A Craig Mackinnon; Marcello DiStasio; Malay Kumar Basu; German Pihan; Saul Suster
Journal:  Mod Pathol       Date:  2022-02-10       Impact factor: 8.209

4.  Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type of thymoma.

Authors:  Yukari Miki; Kana Hamada; Tadashi Yoshino; Katsuya Miyatani; Kiyoshi Takahashi
Journal:  Virchows Arch       Date:  2014-05-07       Impact factor: 4.064

5.  β-catenin activation drives thymoma initiation and progression in mice.

Authors:  Chih-Chia Liang; Tsai-Ling Lu; Yi-Ru Yu; Li-Ru You; Chun-Ming Chen
Journal:  Oncotarget       Date:  2015-06-10

6.  CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets.

Authors:  Jumpei Kashima; Tsunekazu Hishima; Yusuke Okuma; Hirotoshi Horio; Masumi Ogawa; Yukiko Hayashi; Shin-Ichiro Horiguchi; Toru Motoi; Tetsuo Ushiku; Masashi Fukayama
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

Review 7.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

8.  Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.

Authors:  Mark Kriegsmann; Thomas Muley; Alexander Harms; Luca Tavernar; Torsten Goldmann; Hendrik Dienemann; Esther Herpel; Arne Warth
Journal:  Diagn Pathol       Date:  2015-12-08       Impact factor: 2.644

9.  EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes.

Authors:  Su Yudong; Meng Zhaoting; Wang Xinyue; Lin Li; Xu Xiaoyan; Zuo Ran; Chen Jinliang; Chen Peng
Journal:  Thorac Cancer       Date:  2018-05-08       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.